Related references
Note: Only part of the references are listed.Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study
A. Chiricozzi et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study
M. Esposito et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Adalimumab Dose Tapering in Psoriasis: Predictive Factors for Maintenance of Complete Clearance
Katharina Hansel et al.
ACTA DERMATO-VENEREOLOGICA (2017)
Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics
P. Sator et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
Use of Biologic Agents in Combination with Other Therapies for the Treatment of Psoriasis
Jennifer C. Cather et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2014)
A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis
U. Mrowietz et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)
Treatment of Moderate to Severe Plaque Psoriasis With Biologics: Analysis of the Additional Cost of Temporary Dose Escalation vs Switch to Another Biologic After Failure of Maintenance Therapy
L. Puig
ACTAS DERMO-SIFILIOGRAFICAS (2014)
Survival rate of antitumour necrosis factor- treatments for psoriasis in routine dermatological practice: a multicentre observational study
M. Esposito et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Off-Label Biologic Regimens in Psoriasis: A Systematic Review of Efficacy and Safety of Dose Escalation, Reduction, and Interrupted Biologic Therapy
Elizabeth A. Brezinski et al.
PLOS ONE (2012)
Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study
Bruce E. Strober et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2011)
Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study
R. T. Woolf et al.
BRITISH JOURNAL OF DERMATOLOGY (2010)
Experience with biologics for psoriasis in daily practice: switching is worth a try
L. L. A. Lecluse et al.
BRITISH JOURNAL OF DERMATOLOGY (2009)
Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome
R. J. B. Driessen et al.
BRITISH JOURNAL OF DERMATOLOGY (2009)
Adalimumab treatment for severe recalcitrant chronic plaque psoriasis
C. Ryan et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2009)
Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation
C. L. Martyn-Simmons et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2009)
Adalimumab for severe psoriasis and psoriatic arthritis: An open-label study in 30 patients previously treated with other biologics
Marina Papoutsaki et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2007)
Novel immunotherapies for psoriasis: Clinical research delivers new hope for patients and scientific advances
AB Gottlieb
JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS (2004)
Share Paper
